Lexeo announces positive interim Phase 1/2 data for LX1001 gene therapy in APOE4 Alzheimer's

Lexeo Therapeutics, Inc.

LX1001 showed dose-dependent APOE2 expression in all participants with durability to 12 months.
CSF tau biomarkers (T-tau, P-tau181, P-tau217, P-tau231) reduced in >2/3 of participants relative to baseline.
No reports of ARIA; four SAEs reported, one hearing loss possibly related, repeat audiometry pending.
Company initiated FDA engagement; expects update on regulatory interactions and development plans in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.